These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 9523354)
1. Clinical significance of serum P53 antibody in patients with gastric cancer. Shiota G; Ishida M; Noguchi N; Takano Y; Oyama K; Okubo M; Katayama S; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Ito H; Kawasaki H Res Commun Mol Pathol Pharmacol; 1998 Jan; 99(1):41-51. PubMed ID: 9523354 [TBL] [Abstract][Full Text] [Related]
2. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Maehara Y; Kakeji Y; Watanabe A; Baba H; Kusumoto H; Kohnoe S; Sugimachi K Cancer; 1999 Jan; 85(2):302-8. PubMed ID: 10023696 [TBL] [Abstract][Full Text] [Related]
3. [Serum anti-p53 antibodies in gastric cancer patients]. Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and immunohistochemical markers after radical gastrectomy for gastric cancer. Potrc S; Gadiijev E; Hajdinjak T; Kavalar R Hepatogastroenterology; 2007; 54(73):308-14. PubMed ID: 17419281 [TBL] [Abstract][Full Text] [Related]
5. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Wang CS; Wu TL; Tsao KC; Sun CF Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233 [TBL] [Abstract][Full Text] [Related]
6. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Wu CW; Lin YY; Chen GD; Chi CW; Carbone DP; Chen JY Br J Cancer; 1999 May; 80(3-4):483-8. PubMed ID: 10408857 [TBL] [Abstract][Full Text] [Related]
7. Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Bani-Hani KE; Almasri NM; Khader YS; Sheyab FM; Karam HN Clin Cancer Res; 2005 Feb; 11(4):1447-53. PubMed ID: 15746045 [TBL] [Abstract][Full Text] [Related]
8. Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers. Wang JY; Hsieh JS; Chen CC; Tzou WS; Cheng TL; Chen FM; Huang TJ; Huang YS; Huang SY; Yang T; Lin SR J Surg Res; 2004 Aug; 120(2):242-8. PubMed ID: 15234219 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Sumiyoshi Y; Kakeji Y; Egashira A; Mizokami K; Orita H; Maehara Y Clin Cancer Res; 2006 Sep; 12(17):5112-7. PubMed ID: 16951228 [TBL] [Abstract][Full Text] [Related]
10. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298 [TBL] [Abstract][Full Text] [Related]
11. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of different biological markers (DNA index, PCNA index, apoptosis, p53, karyotype) in 126 adenocarcinoma gastric biopsies. Matturri L; Biondo B; Cazzullo A; Colombo B; Giordano F; Guarino M; Pallotti F; Turconi P; Lavezzi AM Anticancer Res; 1998; 18(4B):2819-25. PubMed ID: 9713468 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis. Maehara Y; Tomoda M; Hasuda S; Kabashima A; Tokunaga E; Kakeji Y; Sugimachi K Br J Cancer; 1999 Mar; 79(7-8):1255-61. PubMed ID: 10098768 [TBL] [Abstract][Full Text] [Related]
14. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916 [TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. Al-Moundhri MS; Nirmala V; Al-Hadabi I; Al-Mawaly K; Burney I; Al-Nabhani M; Thomas V; Ganguly SS; Grant C J Surg Oncol; 2005 Sep; 91(4):243-52. PubMed ID: 16121348 [TBL] [Abstract][Full Text] [Related]
17. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors? Zafirellis K; Karameris A; Milingos N; Androulakis G Anticancer Res; 2005; 25(5):3629-36. PubMed ID: 16101192 [TBL] [Abstract][Full Text] [Related]
18. Pre-operative serum levels of sialyl Tn antigen predict liver metastasis and poor prognosis in patients with gastric cancer. Nakagoe T; Sawai T; Tsuji T; Jibiki M; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K; Ishikawa H Eur J Surg Oncol; 2001 Dec; 27(8):731-9. PubMed ID: 11735169 [TBL] [Abstract][Full Text] [Related]
19. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677 [TBL] [Abstract][Full Text] [Related]
20. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]